KRYS - Company ID 0001711279
The table below shows Krystal Biotech, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $80.38M | $30.97M | $15.89M | -$26.16M | -$15.49M | -$9.65M |
| Capital expenditure | $7.15M | $6.20M | $1.26M | $5.38M | $17.19M | $2.47M |
| Investing cash flow | -$63.58M | -$54.77M | -$25.98M | $3.56M | -$55.91M | -$747.00K |
| Dividends paid | - | - | - | - |
Krystal Biotech, Inc. reported operating cash flow of $200.87M for fiscal year 2025. That is up 62.7% from $123.42M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$9.45M (FY 2018) to $200.87M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$10.46M | -$12.47M | $10.58M | $1.47M | -$542.00K | $144.30M |